Peptide Conjugates Targeting p32 for Atherosclerotic Plaque Reduction
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current treatments for atherosclerosis face challenges in effectively targeting and reducing atherosclerotic plaques due to limited access of therapeutic agents and significant side effects, with existing molecular signatures and targeting methods not fully addressing the need for precise delivery and inhibition of plaque formation.
Innovation Solution
Compositions and methods utilizing plaque-homing elements, CendR-activating elements, and plaque-inhibiting elements, such as peptides and small molecule compounds, that specifically bind to p32 and activate the CendR pathway to target and reduce atherosclerotic plaques by promoting apoptosis and enhancing drug delivery.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If conventional therapeutic agents are used to treat atherosclerosis, then some treatment benefit is achieved, but side effects increase and access to plaque interior remains limited
Solution Approach 1:
The therapeutic approach is segmented into multiple functional components: a plaque-homing element (peptide) for targeted delivery, a CendR-activating element for pathway activation, and a plaque-inhibiting element for therapeutic effect. This segmentation allows each component to perform its specific function optimally while reducing off-target effects.
Solution Approach 2:
The plaque-homing peptide acts as an intermediary that delivers the therapeutic agent specifically to plaque tissue. The CendR pathway serves as an intermediary mechanism that facilitates trans-endothelial transport, enabling the therapeutic to reach the plaque interior without affecting healthy tissues.
2Reliability
If conventional therapeutic agents are used to treat atherosclerosis, then some treatment benefit is achieved, but access to plaque interior remains limited
Solution Approach 1:
The CendR pathway serves as an intermediary transport mechanism that facilitates the delivery of therapeutic agents across the endothelial barrier and into the plaque interior. This pathway activation enables deep plaque penetration that conventional agents cannot achieve.
Solution Approach 2:
The invention changes the delivery parameters by using a peptide-based system with specific molecular properties (small size, positive charge, specific binding affinity) that enable it to exploit the CendR pathway for enhanced trans-endothelial transport and plaque penetration.
3Measurement precision
If plaque-targeting peptides are used to home to atherosclerotic plaques, then targeted delivery is improved, but the complexity of the composition increases
Solution Approach 1:
Multiple functional elements (plaque-homing peptide, CendR-activating sequence, therapeutic agent) are merged into a single conjugate or composition. This consolidation achieves precise targeting and enhanced delivery while maintaining a relatively simple overall structure that can be administered as a single therapeutic agent.
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
The described approach enables targeted reduction of atherosclerotic plaques with enhanced drug delivery, reducing plaque load and inhibiting atherosclerosis progression while minimizing side effects by utilizing specific peptide sequences and activation pathways to penetrate and accumulate within plaques.
Implementation Method 1
The plaque-homing element can bind to p32
Implementation Method 2
activate the CendR pathway to target and reduce atherosclerotic plaques by promoting apoptosis and enhancing drug delivery
Implementation Method 3
target and reduce atherosclerotic plaques by promoting apoptosis
Data Source
AI summary
Disclosed are compositions and methods for treatment of atherosclerosis and atherosclerotic plaques. In some forms, the compositions and methods can prevent, inhibit, or reduce atherosclerosis. In some forms, the compositions and methods can prevent, inhibit, or reduce atherosclerotic plaques. In particular, compositions comprising a plaque-homing element, a CendR-activating element, and a plaque-inhibiting element are disclosed.